comprehensive -WSS

comprehensive

author：fashion 2025-09-29 22:46:52 - browse：64

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： A public scorecard can help hold safety

WSS

AI can’t replace a physician’s gut feeling

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Mississippi candidates for statewide offices square off in party primaries

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

AI can’t replace a physician’s gut feeling

Doctors find melanoma drugs effective against rare brain cancer

explore

comprehensive

focus

United colonoscopy coverage change 'may cost lives,' doctors say

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

Affirmative action in medical school literally saved lives

The UK government moves asylum

Medical records are filled with copy

At Orexo, a ‘turning point’ for everything but digital health

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Trump Jan. 6 attorney John Lauro is ex

ChatGPT in medicine: STAT answers readers' burning questions

Sanders adds drug shortage policies to pandemic preparedness bill

explore

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

In early work, researchers turn to CRISPR to treat Alzheimer's

Moderna hits safety problems in bold bid to reinvent medicine

Moderna hits safety problems in bold bid to reinvent medicine

Custom gene therapy hints at new path for rare disease treatments

A public scorecard can help hold safety

Wikipedia

explore

focus

focus